<DOC>
	<DOC>NCT01517009</DOC>
	<brief_summary>The purpose of this study is to determine the feasibility of chemotherapy, consisting of docetaxel, cisplatin and capecitabine given prior to surgery for stomach cancer. Furthermore, an extended type of removal of lymph nodes will be implemented.</brief_summary>
	<brief_title>A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>IbIVa histological proven resectable gastric adenocarcinoma, including gastrooesophageal junction/cardia carcinoma Siewert 2 and 3 ASA 2 or less Age 18 years or more No prior radio or chemotherapy conflicting with the treatment of gastric cancer Haematology/Renal function/Liver function within designated range Patient's consent form obtained, signed and dated before beginning specific protocol procedures absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and followup schedule; those conditions should be discussed with the patient before registration in the trial before patient registration/randomization, written informed consent must be given according to GCP, WMO and local regulations. Previous or other current malignancies, with the exception of adequately treated in situ carcinoma of the cervix uteri or nonmelanoma skin cancer Other current serious illness or medical conditions Severe cardiac illness (NYHA class IIIIV) Significant neurologic or psychiatric disorders Uncontrolled infections Active DIC Other serious underlying medical conditions that could impair the ability of the patient to participate in the study Known hypersensitivity to docetaxel (or any drug formulated with Polysorbate80), or cisplatin or capecitabine or 5FU Definite contraindications for the use of corticosteroids Use of immunosuppressive or antiviral drugs Any other experimental drugs within a 4week period prior to start of neoadjuvant chemotherapy and throughout the study period Pregnant or lactating women Patients with reproductive potential not implementing adequate contraceptive measures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Neo-adjuvant chemotherapy</keyword>
	<keyword>D1extra-resection</keyword>
</DOC>